Absci Highlights Progress and Updates Across Proprietary Pipeline and Leading AI Platform at 2024 R&D Day
Absci (NASDAQ: ABSI) announced significant updates across its pipeline and AI platform at its 2024 R&D Day. The company highlighted progress on several drug candidates:
ABS-201, a novel anti-PRLR antibody for androgenic alopecia, demonstrated improved hair regrowth compared to minoxidil in preclinical trials, targeting a market of approximately 80 million individuals in the U.S. Phase 1 trials are expected to begin in 1H 2026.
ABS-101, an anti-TL1A antibody, showed promising safety profile in 13-week toxicology studies, with Phase 1 trials anticipated in 1H 2025. The company also reported progress on ABS-301 for immuno-oncology and ABS-501, a novel anti-HER2 antibody. Additionally, Absci achieved a breakthrough in designing antibodies targeting the HIV 'caldera' region, potentially advancing universal HIV vaccine development.
Absci (NASDAQ: ABSI) ha annunciato aggiornamenti significativi riguardo al suo pipeline e alla sua piattaforma AI durante il giorno di R&D 2024. L'azienda ha messo in evidenza i progressi su diversi candidati farmaci:
ABS-201, un anticorpo anti-PRLR innovativo per l'alopecia androgenetica, ha dimostrato un miglioramento nella ricrescita dei capelli rispetto al minoxidil in studi preclinici, mirando a un mercato di circa 80 milioni di individui negli Stati Uniti. Gli studi di Fase 1 sono previsti per l'inizio della prima metà del 2026.
ABS-101, un anticorpo anti-TL1A, ha mostrato un profilo di sicurezza promettente in studi di tossicologia di 13 settimane, con gli studi di Fase 1 attesi nella prima metà del 2025. L'azienda ha anche riportato progressi su ABS-301 per l'immuno-oncologia e ABS-501, un anticorpo anti-HER2 innovativo. Inoltre, Absci ha raggiunto una svolta nella progettazione di anticorpi mirati alla regione 'caldera' dell'HIV, potenzialmente favorendo lo sviluppo di un vaccino universale contro l'HIV.
Absci (NASDAQ: ABSI) anunció actualizaciones significativas en su pipeline y plataforma de IA en su Día de I&D 2024. La compañía destacó los avances en varios candidatos a fármacos:
ABS-201, un anticuerpo anti-PRLR novedoso para la alopecia androgénica, demostró una mejor regeneración del cabello en comparación con el minoxidil en ensayos preclínicos, apuntando a un mercado de aproximadamente 80 millones de individuos en EE. UU. Se espera que los ensayos de Fase 1 comiencen en la primera mitad de 2026.
ABS-101, un anticuerpo anti-TL1A, mostró un perfil de seguridad prometedor en estudios de toxicología de 13 semanas, con ensayos de Fase 1 anticipados en la primera mitad de 2025. La compañía también reportó avances en ABS-301 para inmuno-oncología y ABS-501, un anticuerpo anti-HER2 novedoso. Además, Absci logró un avance en el diseño de anticuerpos dirigidos a la región 'caldera' del VIH, lo que podría avanzar en el desarrollo de una vacuna universal contra el VIH.
Absci (NASDAQ: ABSI)는 2024년 연구개발의 날에 파이프라인 및 인공지능 플랫폼 전반에 걸쳐 중요한 업데이트를 발표했습니다. 회사는 여러 약물 후보에 대한 진전을 강조했습니다:
ABS-201, 남성형 탈모를 위한 새로운 항-PRLR 항체는 전임상 시험에서 미녹시딜에 비해 개선된 모발 재생을 보여주었으며, 미국 내 약 8천만 명의 개인을 대상으로 하는 시장을 겨냥하고 있습니다. 1상 시험은 2026년 상반기에 시작될 것으로 예상됩니다.
ABS-101, 항-TL1A 항체는 13주 독성 연구에서 유망한 안전성 프로필을 보여주었으며, 1상 시험은 2025년 상반기에 예정되어 있습니다. 회사는 또한 ABS-301 면역종양학 및 ABS-501, 새로운 항-HER2 항체에 대한 진전을 보고했습니다. 게다가, Absci는 HIV '칼데라' 지역을 겨냥한 항체 설계에서 획기적인 성과를 달성하여 범용 HIV 백신 개발을 앞으로 나아갈 가능성을 제시했습니다.
Absci (NASDAQ: ABSI) a annoncé des mises à jour significatives concernant son pipeline et sa plateforme d'IA lors de sa journée R&D 2024. L'entreprise a mis en avant des progrès sur plusieurs candidats médicaments :
ABS-201, un nouvel anticorps anti-PRLR pour l'alopécie androgénique, a montré une meilleure repousse des cheveux par rapport au minoxidil dans des essais précliniques, ciblant un marché d'environ 80 millions de personnes aux États-Unis. Les essais de phase 1 devraient commencer au premier semestre 2026.
ABS-101, un anticorps anti-TL1A, a montré un profil de sécurité prometteur dans des études de toxicologie de 13 semaines, avec des essais de phase 1 anticipés pour le premier semestre 2025. L'entreprise a également rapporté des progrès sur ABS-301 pour l'immuno-oncologie et ABS-501, un nouvel anticorps anti-HER2. De plus, Absci a réalisé une avancée dans la conception d'anticorps ciblant la région 'caldera' du VIH, ce qui pourrait faire progresser le développement d'un vaccin universel contre le VIH.
Absci (NASDAQ: ABSI) gab bedeutende Updates zu seinem Pipeline und seiner KI-Plattform während seines F&E-Tages 2024 bekannt. Das Unternehmen hob Fortschritte bei mehreren Arzneimittelkandidaten hervor:
ABS-201, ein neuartiger Anti-PRLR-Antikörper gegen androgenetische Alopezie, zeigte in präklinischen Studien eine verbesserte Haarneuwachstumsrate im Vergleich zu Minoxidil und zielt auf einen Markt von etwa 80 Millionen Menschen in den USA ab. Die Phase-1-Studien sollen in der ersten Hälfte von 2026 beginnen.
ABS-101, ein Anti-TL1A-Antikörper, zeigte ein vielversprechendes Sicherheitsprofil in 13-wöchigen Toxikologie-Studien, wobei Phase-1-Studien in der ersten Hälfte von 2025 erwartet werden. Das Unternehmen berichtete auch über Fortschritte bei ABS-301 für die Immunonkologie und ABS-501, einem neuartigen Anti-HER2-Antikörper. Darüber hinaus erzielte Absci einen Durchbruch bei der Gestaltung von Antikörpern, die auf die HIV-'Caldera'-Region abzielen, was möglicherweise die Entwicklung eines universellen HIV-Impfstoffs vorantreiben könnte.
- Drug candidate selected for ABS-201 with demonstrated superior hair regrowth compared to existing treatment
- Large market opportunity with 80 million potential patients in U.S. for ABS-201
- ABS-101 showed favorable safety profile in 13-week toxicology studies
- Breakthrough in targeting previously difficult-to-drug HIV epitope
- ABS-201 Phase 1 trials not starting until 1H 2026
- Multiple drug candidates still in early development stages
Insights
The R&D Day updates reveal significant progress in Absci's AI-driven drug development platform. The highlight is ABS-201, targeting a massive market of 80 million U.S. patients with androgenic alopecia. The preclinical data showing superior efficacy to minoxidil, combined with convenient dosing and favorable safety profile, positions it as a potential breakthrough treatment. The anticipated Phase 1 trial in 1H 2026 marks a clear development timeline.
The pipeline expansion with ABS-501, a novel HER2 antibody showing efficacy against trastuzumab-resistant tumors, demonstrates the platform's ability to address existing treatment limitations. The HIV caldera targeting breakthrough validates their AI platform's capability to tackle previously "undruggable" targets.
This comprehensive pipeline update strengthens Absci's market position in the AI-driven drug discovery space. The company is strategically targeting high-value markets - particularly with ABS-201 addressing the lucrative hair loss segment, which has significant commercial potential given the large addressable market and consumer-driven nature. The advancement of multiple candidates toward clinical trials in 2025-2026 provides clear value-creation milestones.
The platform validation through the HIV antibody breakthrough could attract more pharmaceutical partnerships, potentially leading to increased collaboration revenue. With a market cap of
Drug candidate selected for ABS-201, a novel, potentially category-defining anti-PRLR antibody in development for androgenic alopecia
Leading AI platform demonstrated breakthrough in successful de novo design of antibody targeting previously difficult-to-drug epitope in the HIV “caldera” region
VANCOUVER, Wash. and NEW YORK, Dec. 12, 2024 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a data-first generative AI drug creation company, today announced updates and progress across its internal pipeline of proprietary Drug Creation programs, as well as new breakthroughs demonstrated by Absci’s AI Integrated Drug Creation™ platform. Absci leadership and a series of distinguished guest speakers will be presenting on these updates today at Absci’s 2024 R&D Day.
“Today’s updates represent another major step forward for Absci, as we continue to demonstrate our leadership in de novo AI antibody design, which is driving significant advancements in our internal and partnered programs,” said Sean McClain, Founder and CEO. “We are excited to showcase the target and significant opportunities we see for ABS-201, present new data for ABS-101 and ABS-301, and introduce ABS-501 to our pipeline. ABS-201, a potential treatment for male and female pattern hair loss, represents an opportunity to unlock an entirely new category of therapy for a substantial consumer-driven market with significant clinical unmet need. And as we near the end of 2024, we see next year as an opportunity to reach multiple milestones across our internal portfolio, and maintain a robust pipeline of potential partners across the Pharma and broader healthcare industry landscape.”
Speakers and topics to be covered during today’s presentation include:
Absci Leadership
- Sean McClain, Founder & CEO, Absci
- Andreas Busch, PhD, Chief Innovation Officer, Absci
- Zach Jonasson, PhD, Chief Financial Officer & Chief Business Officer, Absci
- Amaro Taylor-Weiner, PhD, Chief AI Officer, Absci
- Christian Stegmann, PhD, SVP Drug Creation, Absci
Guest Presenters
- Sir Mene Pangalos, PhD, Biopharmaceutical Executive; Board Director, Absci; Co-Chair, Absci Scientific Advisory Board
- Dr. Luis Diaz, MD, Head of the Division of Solid Tumor Oncology, Memorial Sloan Kettering Cancer Center; Advisor, Absci
- Dr. Dennis Slamon, MD, PhD, Chief of Division of Hematology and Oncology, UCLA Medicine
- Karl Ziegelbauer, PhD, Chief Scientific Officer, Almirall
- Dr. Anthony Rossi, MD, Attending Dermatologist, Memorial Sloan Kettering Cancer Center; Professor of Dermatology, Weill Cornell Medical College; Advisor, Absci
- Mike Jafar, Medical Aesthetics Executive; Advisor, Absci
ABS-201
ABS-201 is a potential best-in-class anti-PRLR antibody in development for androgenic alopecia, an indication with significant clinical unmet need and a large potential patient population of approximately 80 million individuals in the U.S. alone.
- Absci has nominated a drug candidate with preclinical profile suggesting:
- High affinity and potency
- Favorable safety and immunogenicity
- Extended half-life for convenient infrequent dosing
- Excellent developability and manufacturability
- Preclinical model demonstrates improved hair regrowth compared to minoxidil
- ABS-201 has potential to offer a safe option as compared to current standard of care
- Anticipate initiation of Phase 1 clinical trial in 1H 2026
ABS-101
ABS-101 is a potential best-in-class anti-TL1A antibody that demonstrates high affinity and potency, ability to bind the monomer and trimer of TL1A, anticipated low immunogenicity, high bioavailability in non-human primates, and potential to be administered subcutaneously with an anticipated dosing interval of 8-12 weeks, or even less frequently.
- ABS-101 shows reduced internalization of TL1A complexes in in vitro THP-1 immunogenicity tests compared to a competitor molecule with a high clinical anti-drug antibody (ADA) rate.
- This suggests a lower chance of developing ADAs in clinical settings, as internalization of mAb:TL1A complexes could contribute to immune activation and ADA formation.
- 13-week GLP toxicology studies: No treatment-related adverse findings during in-life phase and necropsy were observed; histopathology is pending.
- Anticipate initiation of Phase 1 clinical trial in 1H 2025
ABS-301
ABS-301 is a potential first-in-class antibody for an undisclosed immuno-oncology target, discovered through Absci’s AI Reverse Immunology target discovery platform.
- Expression of ABS-301’s target suggests broad potential in squamous cell carcinomas and beyond.
- For this program, Absci has optimized an antibody lead with high affinity and potency, and anticipates selecting a drug candidate in 1H 2025.
ABS-501
ABS-501 is a potential best-in-class novel AI-designed anti-HER2 antibody.
- Absci has identified lead molecules using its zero-shot de novo AI technology with the following characteristics:
- Novel epitope interactions
- Increased or equivalent affinity to trastuzumab in preclinical settings
- Efficacious against a trastuzumab-resistant xenograft tumor expressing wild-type HER2
- Good developability
- Anticipate selection of a drug candidate in 2025, and multiple paths for therapeutic development of this program are under consideration.
AI Platform Breakthrough Demonstrated through Collaboration with California Institute of Technology
- Absci has achieved a breakthrough by de novo designing an antibody that targets a previously difficult-to-drug epitope in the HIV “caldera” region. This breakthrough potentially aids the development of a universal HIV vaccine.
- Leveraging its proprietary de novo antibody design model AbsciDesign, Absci created antibodies targeting a highly conserved and structurally challenging region of the HIV gp120 protein. The “caldera” region, uniquely accessible only in the open conformation of gp120, has remained untargeted by previous broadly neutralizing antibodies.
- Preliminary screening data indicates that designs bind clades A, B, and C with selective binding to open conformation. Antibodies from this study will be further experimentally evaluated to confirm fidelity of the de novo designed structure and epitope specificity.
- Successful creation of these antibodies marks a potential pivotal milestone in HIV vaccine research and underscores the capability of AbsciDesign to target conserved epitopes that were previously considered out of reach.
A live and archived webcast of Absci’s 2024 R&D Day may be accessed via the company’s investor relations website at: investors.absci.com.
About Absci
Absci is a data-first generative AI drug creation company that combines AI with scalable wet lab technologies to create better biologics for patients, faster. Our Integrated Drug Creation™ platform unlocks the potential to accelerate time to clinic and increase the probability of success by simultaneously optimizing multiple drug characteristics important to both development and therapeutic benefit. With the data to train, the AI to create, and the wet lab to validate, we can screen billions of cells per week, allowing us to go from AI-designed candidates to wet lab-validated candidates in as little as six weeks. Absci’s headquarters is in Vancouver, WA, with our AI Research Lab in New York City and an Innovation Center in Zug, Switzerland. Visit www.absci.com and follow us on LinkedIn (@absci), X (Twitter) (@Abscibio), and YouTube.
Investor Contact
Alex Khan
VP, Finance & Investor Relations
investors@absci.com
Media Contact
press@absci.com
FAQ
When will Absci (ABSI) begin Phase 1 trials for ABS-201?
What is the market size for Absci's (ABSI) ABS-201 drug candidate?
What breakthrough did Absci (ABSI) achieve in HIV research?
When will Absci (ABSI) begin Phase 1 trials for ABS-101?
How did ABS-201 perform compared to existing treatments in preclinical trials?
